IL-15-engineered UCMSCs can specifically home to pancreatic cancer sites, and a sufficient amount of UCMSC-IL15 has been observed to survive to release IL-15, which could significantly suppress the growth of pancreatic cancer [97]. This evidence concerns the gene IL15 and familial pancreatic carcinoma.